Irbesartan Diabetic Nephropathy Trial - IDNT

Description:

The Irbesartan Diabetic Nephropathy Trial (IDNT) was a randomized, blinded, placebo-controlled trial designed to assess whether irbesartan or amlodipine slow the progression of nephropathy in patients with type 2 diabetes, independent of effects on systemic blood pressure (BP) lowering.